BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Clinical safety rating: avoid
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
| Metabolism | Primarily metabolized by hepatic esterases to salicylate; conjugation with glycine (salicyluric acid) and glucuronic acid (salicyl phenolic glucuronide) mainly in the liver; also metabolized by cytochrome P450 (CYP) enzymes (CYP2C9) to a lesser extent. |
| Excretion | Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance. |
| Half-life | Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing. |
| Protein binding | 80-90% bound to serum albumin, primarily binding site I (warfarin site). Binding is saturable and decreases at high concentrations, increasing free fraction and toxicity risk. |
| Volume of Distribution | 0.15-0.2 L/kg for aspirin; for salicylate 0.1-0.2 L/kg. Low Vd reflects limited extravascular distribution; does not extensively penetrate brain except at high doses (therapeutic for migraine likely CNS penetration via passive diffusion). |
| Bioavailability | Oral immediate-release aspirin: 50-75% (due to first-pass hydrolysis in GI mucosa and liver). Enteric-coated: reduced and delayed absorption. Rectal: 20-50% (variable). For BAYER EXTRA STRENGTH ASPIRIN (500 mg), ~60% bioavailability. |
| Onset of Action | Oral (immediate-release): Analgesic effect begins within 15-30 minutes. Peak plasma salicylate at 1-2 hours. For migraine, efficacy typically noted within 1 hour. |
| Duration of Action | Analgesic effect lasts 4-6 hours for immediate-release formulation. Antiplatelet effect lasts 7-10 days (irreversible COX-1 inhibition). Duration may be shorter for migraine due to rapid absorption and distribution. |
| Molecular Weight | 180.16 |
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 10-50 mL/min: avoid or reduce dose to 500 mg every 6 hours; GFR <10 mL/min: contraindicated. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% or extend interval to 8 hours; Class C: contraindicated. |
| Pediatric use | Weight <40 kg: 10-15 mg/kg orally every 4-6 hours, maximum 60 mg/kg/day; Weight ≥40 kg: adult dosing. |
| Geriatric use | Start at lowest effective dose (500 mg every 6-8 hours); monitor renal function and bleeding risk. |
| 1st trimester | Avoid: Associated with increased risk of miscarriage and congenital anomalies (e.g., gastroschisis). Use only if clearly needed with lowest effective dose. |
| 2nd trimester | Caution: Use only if clearly needed. Avoid high doses; may affect maternal and fetal hemostasis. |
| 3rd trimester | Avoid: Risk of premature closure of ductus arteriosus, oligohydramnios, and peripartum hemorrhage. NSAIDs including aspirin are contraindicated in the third trimester. |
Clinical note
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
| FDA category | Positive |
| Placental transfer | Aspirin crosses the placenta. The transfer is dependent on dose and maternal serum levels. Higher transfer occurs with anti-inflammatory doses compared to low-dose aspirin. |
■ FDA Black Box Warning
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
| Common Effects | fever |
| Serious Effects |
Hypersensitivity to aspirin or NSAIDsActive peptic ulcer diseaseHistory of aspirin-exacerbated respiratory disease (e.g., asthma, rhinitis)Severe hepatic impairmentSevere renal impairment (eGFR <30 mL/min)Third trimester of pregnancyBleeding disorders (e.g., hemophilia, von Willebrand disease)Concomitant use of methotrexate (>15 mg/week) or anticoagulants (unless closely monitored)
| Precautions | Increased risk of gastrointestinal bleeding, ulcers, and perforation; hypersensitivity reactions including anaphylaxis; increased bleeding risk; severe hepatic injury; caution in patients with asthma, G6PD deficiency, renal impairment, or history of peptic ulcer disease. |
| Food/Dietary |
Loading safety data…
| Breastfeeding | Aspirin is excreted into breast milk in low amounts. After single doses, concentrations are minimal. Regular high-dose aspirin may cause adverse effects in infants (e.g., Reye's syndrome, platelet dysfunction). Avoid or use lowest effective dose for short periods. |
| Lactation Rating | L3 (Moderately Safe) - single doses; L4 (Possibly Hazardous) - chronic high doses |
| Teratogenic Risk | First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: Avoid due to potential effects on fetal renal function and premature closure of ductus arteriosus, though risk is lower than third trimester. Third trimester: Contraindicated. Use in third trimester increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage in the fetus; may prolong gestation and labor. |
| Fetal Monitoring | Maternal: Monitor for signs of bleeding (e.g., gum bleeding, epistaxis, bruising), prolonged gestation, and postpartum hemorrhage. Monitor platelet function if used near term. Fetal/Neonatal: Monitor for premature closure of ductus arteriosus (fetal echocardiography if used in third trimester), oligohydramnios (ultrasound), and neonatal bleeding disorders if used near delivery. |
| Fertility Effects | Aspirin may impair female fertility by inhibiting prostaglandin synthesis, potentially interfering with ovulation and implantation. Reversible upon discontinuation. No known effect on male fertility. |
| High-fat meals may delay absorption and reduce efficacy. Avoid alcohol to minimize GI bleeding risk. No significant food interactions beyond general GI irritation, but taking with food may improve tolerance. |
| Clinical Pearls | For migraine pain, aspirin 500-1000 mg (equivalent to 2-4 tablets of Bayer Extra Strength) is recommended at onset. Note that aspirin is contraindicated in patients with a history of nasal polyps, angioedema, or bronchospasm with NSAIDs. Monitor for tinnitus or hearing loss as signs of salicylate toxicity. Avoid use within 48 hours of alcohol cessation therapy due to GI irritation. |
| Patient Advice | Take this medication at the first sign of migraine pain for best results. · Do not exceed 8 tablets (4000 mg aspirin) in 24 hours. · Avoid alcohol while taking aspirin to reduce risk of stomach bleeding. · Do not use if you have a history of stomach ulcers, bleeding disorders, or asthma triggered by aspirin. · Consult a doctor if your migraine does not improve after 1-2 doses or if you have severe symptoms. · Keep out of reach of children; Reye's syndrome warning if given to children or teenagers with viral illness. |